NCT03968952 is a NA clinical trial of SMARThealth Pregnancy in Pre-Eclampsia, sponsored by University of Oxford.

Who is sponsoring NCT03968952?

NCT03968952 is sponsored by University of Oxford.

What drugs are being tested in NCT03968952?

Interventions in NCT03968952: SMARThealth Pregnancy.

What condition does NCT03968952 study?

NCT03968952 studies Pre-Eclampsia, Gestational Diabetes, Anemia.

Is NCT03968952 still recruiting?

NCT03968952 is currently completed. Last updated 4 November 2020.

Last reviewed 2020-11-04 · How we verify

NCT03968952

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

SMARThealth Pregnancy: Feasibility & Acceptability of a Complex Intervention for High-risk Pregnant Women in Rural India.

Completed NA Last updated 4 November 2020

What this trial tests

NA trial testing SMARThealth Pregnancy in Pre-Eclampsia in 258 participants. Completed in 1 November 2020.

Timeline

1 October 2019

Primary endpoint
14 September 2020

1 November 2020

Quick facts

Lead sponsor	University of Oxford
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	258
Start date	1 October 2019
Primary completion	14 September 2020
Estimated completion	1 November 2020
Sites	1 location across India

Drugs / interventions tested

SMARThealth Pregnancy

Conditions studied

Pre-Eclampsia — all drugs for Pre-Eclampsia →
Gestational Diabetes — all drugs for Gestational Diabetes →
Anemia — all drugs for Anemia →

Sponsor

University of Oxford

Who can join

18 and older, any sex, with Pre-Eclampsia or Gestational Diabetes. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Background: Pregnancy-related conditions including hypertensive disorders of pregnancy (HDPs) and gestational diabetes mellitus (GDM) carry independent risks for future cardiovascular disease in women. Early identification, referral and management of pregnant women at increased risk of future cardiometabolic disorders may offer opportunities for prevention. Objective: To determine the feasibility and acceptability of the SMARThealth Pregnancy intervention to improve the detection, referral and management of pregnant women at high-risk of future cardiometabolic disorders in rural India. Study design: Cluster randomised pilot study of 4 primary care centres (PHCs) in two diverse areas of rural India. Outcome: The primary objective of this pilot study is to address the feasibility of the SMARThealth Pregnancy intervention.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A Mobile Clinical Decision Support System for High-Risk Pregnant Women in Rural India (SMARThealth Pregnancy): Pilot Cluster Randomized Controlled Trial.
Nagraj S, Kennedy S, Jha V, Norton R, et al · · 2023 · cited 14× · PMID 37471135 · DOI 10.2196/44362
SMARThealth Pregnancy: Feasibility and Acceptability of a Complex Intervention for High-Risk Pregnant Women in Rural India: Protocol for a Pilot Cluster Randomised Controlled Trial.
Nagraj S, Kennedy SH, Jha V, Norton R, et al · · 2021 · cited 10× · PMID 34816187 · DOI 10.3389/fgwh.2021.620759
Digital tracking, provider decision support systems, and targeted client communication via mobile devices to improve primary health care.
Agarwal S, Chin WY, Vasudevan L, Henschke N, et al · · 2025 · cited 9× · PMID 40193137 · DOI 10.1002/14651858.cd012925.pub2

Verify or expand the search:

Other trials of SMARThealth Pregnancy

Trials testing the same drug.

NCT05752955 — SMART Health Pregnancy 2 - Intervention to Reduce Anaemia and Cardiometabolic Risk During Pregnancy and in the First Yea · NA · completed

Other recruiting trials for Pre-Eclampsia

Currently open trials in the same condition.

NCT07245056 — Fetal Fornix and Hippocampus in Pregnant Women With Early-Onset Preeclampsia · NA · recruiting
NCT07187596 — Mortality Outcome of Controlled Hypertension · active not recruiting
NCT06893510 — Virtual Reality-Based and Face-to-Face Relaxation Programs in Pregnant Women With Preeclampsia · NA · recruiting
NCT06122220 — Optic Nerve Sheath Measurement and Angiogenic Factors in Patients With Pre-eclampsia. · NA · recruiting
NCT06779916 — Autophagy/Apoptosis Balance in Placental Vascular Pathologies · recruiting

Other University of Oxford trials

Trials by the same sponsor.

NCT05380388 — A Safety, Immunogenicity and Efficacy Study of PvRII/Matrix-M in Healthy Thai Adults Living in Thailand ( MIST3 ) · Phase 2 · not yet recruiting
NCT07470424 — A Clinical Study of Piperaquine, Pyronaridine, and Artesunate Administered in Combination in Healthy Adults · Phase 1 · not yet recruiting
NCT07345910 — Environment, Pathogens, and Host Interactions in Melioidosis · not yet recruiting
NCT07434973 — Stratification and Treatment in Early Psychosis Study - PROMOTE · Phase 3 · not yet recruiting
NCT07460401 — 'Do Patient Characteristics Associate With Poor Outcome With Femoral Acetabular Impingement Syndrome (FAIS) Following Ph · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03968952 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Oxford
Last refreshed: 4 November 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03968952.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing